Takeda Pharmaceutical Company Limited (TAK)

Every figure this model derived for TAK, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 200,795,000,000 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-03-31
cash 385,113,000,000 CashAndCashEquivalents 2025-03-31
current assets 2,521,192,000,000 CurrentAssets 2025-03-31
current liabilities 2,506,521,000,000 CurrentLiabilities 2025-03-31
equity 6,935,084,000,000 EquityAttributableToOwnersOfParent 2025-03-31
interest expense 137,311,000,000 InterestExpense 2025-03-31
ocf 1,057,182,000,000 CashFlowsFromUsedInOperatingActivities 2025-03-31
revenue 4,581,551,000,000 Revenue 2025-03-31
sbc 73,585,000,000 ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets 2025-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up TAK on one particular measure came for.

RatioValue
cash operating margin25.7
current ratio1.01
current ratio reported1.01
dilution pct1.58
fcf margin18.69
interest cover2.49
net debt ebitda4.26
operating margin7.48
owner earnings margin17.09
revenue growth7.45
revenue growth per share5.78
roic2.33
rule of 4014.93
sbc pct revenue1.61

What to be careful about

What this model itself distrusts about TAK's figures. Written by the derivation as it ran, not added afterwards.